



Pharma **POOL**

Stephen
ANDRZEJEWSKI
Dan **MCCALL**
Adriann **SAX**

King Promotes Staff



King Pharmaceuticals, a vertically integrated pharmaceutical company based in Bristol, Tenn., has promoted Stephen Andrzejewski to chief commercial officer.

Mr. Andrzejewski joined King in May 2004 as corporate head of commercial operations. His expanded responsibilities include business development of the company's Meridian division, along with continuing to lead sales, managed markets, strategic marketing, and the business and marketing groups for King's CNS, CV/endo, hospital, respiratory, and legacy brands.



King also has promoted Dan McCall to senior VP of sales and field operations. Mr. McCall leads national primary-care and specialty sales, as well as sales and marketing operations.

Since joining King in 1997, Mr. McCall has held several positions, most recently serving as senior VP of sales of the eastern division.

King also has appointed Adriann Sax to executive VP of business development and strategic planning. Ms. Sax leads business development, which will be aligned with



strategic marketing and the ongoing focus in key therapeutic areas such as CNS, CV/endo, and hospital.

She originally joined King in April 2005 as senior VP of strategic marketing. Ms. Sax continues to have responsibility for strategic marketing, market research, and forecasting.

Etienne N. **ATTAR**
Dr. Emilio A. **EMINI**

Wyeth Hires and Promotes

Etienne N. Attar has been promoted to the position of president of Wyeth Consumer Healthcare — International, and he has joined the company's operations committee. Wyeth, Madison, N.J., is a research-driven pharmaceutical and healthcare products company.

Mr. Attar, 51, has been with the company for 17 years, most recently serving as senior VP, Canada/Europe, Middle-East, and Africa, for Wyeth Consumer Healthcare. Previously, he held sales and marketing positions with Abbott Laboratories, Bristol-Myers, and Cyanamid Canada. He has a B.S. in biology and a M.S. in toxicology from Concordia University.



Emilio A. Emini, Ph.D., has been named executive VP of vaccines research and development for Wyeth Pharmaceuticals. In this role, Dr. Emini's strategic leadership is focused on research areas, including pneumococcal disease, bacterial meningitis, respiratory diseases, Alzheimer's disease, HIV infection, and sexually transmitted diseases.

He joins Wyeth from the International AIDS Vaccine Initiative, where he was senior

VP for vaccine development. Dr. Emini has a Ph.D. in microbiology from Cornell University Graduate School of Medical Sciences, and he was a postdoctoral fellow in the Department of Microbiology at the State University of New York at Stony Brook.

Jeffrey **BERKOWITZ**

Schering-Plough Promotes
Group VP, U.S.
Managed Markets

Schering-Plough, Kenilworth, N.J., a global science-based healthcare company, has appointed Jeffrey Berkowitz to group VP of U.S. managed markets. He leads the managed markets team and is responsible for trade sales and state government affairs.

Mr. Berkowitz originally joined Schering-Plough in 1998 as senior counsel assigned to the managed-care and specialty-care customer groups, and he has held increasingly responsible positions in global law and U.S. managed markets. In 2004, he was given the Schering-Plough Chairman's Award.

He has a J.D. from Brooklyn Law School and a B.A. in political science from Union College.

John E. **CELENTANO**

Bristol-Myers Squibb Promotes
President of Health Care Group

Bristol-Myers Squibb has promoted John E. Celentano to president of the Health Care Group, responsible for all nonpharmaceutical businesses, including Mead Johnson Nutritionals, ConvaTec, and Bristol-Myers Squibb Medical Imaging. Based in New York, Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company.

Most recently, Mr. Celentano served as president of Latin America and Canada for Bristol-Myers Squibb's pharmaceutical business. He has a MBA from Drexel University and a B.A. from the University of Delaware.

Jeanine **JIGANTI**

TPNA Names
Chief Compliance Officer

Jeanine Jiganti has been named chief compliance officer for Takeda Pharmaceuticals North America (TPNA), Lincolnshire, Ill., a wholly owned subsidiary of Takeda Pharmaceutical.

Ms. Jiganti is responsible for advising senior management of compliance and regulatory issues, as well as promoting compliance with applicable laws and company policies through detection and prevention.

She has come to TPNA from the State of Illinois, where she was the general counsel and ethics officer for the Department of Commerce and Economic Opportunity. She has a bachelor's degree from the University of Colorado and a law degree from Loyola University of Chicago School of Law.

Christopher **PORTER**

Novo Nordisk Appoints Director of Government Affairs

Novo Nordisk has appointed Christopher Porter as director of government affairs in the United States. Novo Nordisk, with U.S. headquarters in Princeton, N.J., is a healthcare company with a broad diabetes portfolio. Mr. Porter leads all of the company's U.S. lobbying activities out of its Washington, D.C., office.

Most recently, he spent five years with YourCongress, where he led the strategic consulting division and specialized in healthcare and appropriations. Mr. Porter holds bachelor's degrees in political science and law and society from The American University, where he graduated cum laude.

Paul **SAATSOGLOU**

David **TREXLER**

Eisai Makes Appointments



Eisai, a human healthcare company based in Teaneck, N.J., has appointed Paul Saatsoglou as senior director of market research and business analytics. He is responsible for building a state-of-the-art marketing research and business analytics function at Eisai.

He previously held positions at IMS Management Consulting, Bristol-Myers Squibb, Janssen, and Pfizer.



Eisai also has appointed David Trexler as director of new products portfolio. He is responsible for identifying, preparing, and executing key premarket conditioning and product development activities.

His previous experience includes positions at Mylan Bertek and Marion Laboratories (now sanofi-aventis), where he spent 18 years.

Cheryl L. **WHITE**

Baxter Names VP

Baxter International, a Deerfield, Ill. com-

pany with expertise in medical devices, pharmaceuticals, and biotechnology, has appointed Cheryl L. White as VP of quality.

Ms. White is serving in this capacity while Baxter conducts a national search for a corporate VP of quality, for which she also is a candidate. Lawrence T. Gibbons, who previously held the position, has left Baxter to pursue other interests.

Ms. White has been with Baxter for eight years, most recently as VP of BioScience Quality Management in Westlake, Calif.

She has a MBA from the University of California, Irvine, and a B.A. in biology from the University of California, San Diego.

Biotech **POOL**

Amy **BOCK**

Dr. Douglas **JACOBY**

Dr. Abdellah **SENTISSI**

Susan **STEWART**

TransMolecular Expands Management Team

TransMolecular, Cambridge, Mass., a biotechnology company focused on cancer drug development, has made key additions to its management team.

Amy Bock has been appointed senior director of clinical operations. She brings 19 years of biotechnology experience in clinical drug development, most recently as director of clinical research in Genzyme's Clinical Strategic Development Group.

Ms. Bock earned a B.S. in biological psychology from Pine Manor College. She also has conducted postgraduate work in cancer biology and immunology at Harvard.

Douglas Jacoby, Ph.D., has joined TransMolecular as senior director of research and development, and he is working to discover new cancer drug mechanisms.

He has joined the company from GenVec, where he was director of research. He earned his Ph.D. in biochemistry from the University of Minnesota and conducted a postdoctoral fellowship at Brandeis University. He has a B.A. in biology from Kenyon College.

TransMolecular has named Abdellah Sentissi, Ph.D., as VP of manufacturing and quality systems.

He previously was with BioVest International as VP of quality systems. He earned a Ph.D. and conducted a postdoctoral fellowship in clinical chemistry at Northeastern

University. He also holds a master's in medical sciences from the University of California in San Francisco and a B.S. in pharmacy from the University of Paul Sabatier.

Additionally, Susan Stewart has joined the company as VP of regulatory affairs. Most recently, she was VP of regulatory affairs at Genzyme and VP of quality and regulatory affairs for MG Biotherapeutics, a joint venture of Medtronic and Genzyme.

Ms. Stewart has conducted postgraduate studies in clinical pharmacology, drug development, and regulation at Tufts University School of Medicine, and she has a B.A. in English from Annhurst College. She also is U.S. and European Union Regulatory Affairs Certified by the Regulatory Affairs Professionals Society.

Michelle **BURRIS**

Rick **HAMM**

Dendreon Makes Organizational Changes

Michelle Burris, senior VP and chief financial officer at Dendreon, a Seattle-based biotechnology company, has expanded her role to head manufacturing operations.

Ms. Burris previously spent 10 years at Corixa, where she played a central role in the successful development and approval of that company's antibody drug for the treatment of non-Hodgkin's lymphoma.

Rick Hamm, senior VP and general counsel, also has expanded his role to include oversight of Dendreon's business development activities. Mr. Hamm joined the company in 2004 from Medtronic.

Dr. Nancy **CHANG**

Dr. Danong **CHEN**

Edward **HU**

Tanox Makes Management Changes

Nancy Chang, Ph.D., has assumed the role of chairman of the board for Tanox, Houston, a biotechnology company specializing in the discovery and development of monoclonal antibodies.

Dr. Chang, a cofounder of the company, previously served as president and CEO. She replaces Osama Mikhail, Ph.D., who has been named lead director.

Danong Chen, Ph.D., has assumed the roles of president and CEO. She also serves on the board of directors.

Dr. Chen most recently served Tanox as VP of strategy and corporate development. Before joining Tanox in 2002, she was a manager in

the healthcare practice of Arthur D. Little. She has a Ph.D. in neuroscience from Baylor College of Medicine and a MBA from the Arthur D. Little School of Management at Boston College.

Additionally, Edward Hu has been promoted to senior VP and chief operating officer. He previously served as VP of operations. Before joining Tanox in October 2000, he was manager of financial planning and analysis with Biogen. Mr. Hu earned his MBA at Carnegie Mellon University, where he also did graduate work in biophysics and biochemistry.

Dr. Russell H. **ELLISON**

FibroGen Appoints VP, Clinical Development

Russell H. Ellison, M.D., has been named VP of clinical development for FibroGen, South San Francisco, Calif., a biotechnology-based drug-discovery company. Dr. Ellison focuses on expansion of FibroGen's clinical development team and rapid advancement of key clinical programs in anemia, diabetic nephropathy, and dermal augmentation through approval and commercialization.

He brings more than 26 years of pharmaceutical industry experience to this new role, most recently as VP of medical affairs and chief medical officer at Sanofi-Synthelabo. He holds a M.D. from the University of British Columbia and an M.Sc. from London University.

Paul J. **HASTINGS**

OncoMed Appoints President and CEO

OncoMed Pharmaceuticals, Mountain View, Calif., has named Paul J. Hastings as president and CEO. OncoMed discovers and develops monoclonal antibodies and small molecules capable of destroying cancer stem cells. Mr. Hastings succeeds the company's founding CEO, James N. Woody, M.D., Ph.D., who remains as chairman of the board of directors.

Most recently, Mr. Hastings, 45, served as president and CEO of QLT. He has a B.S. in pharmacy from the University of Rhode Island.

Dr. Tess **SCHMALBACH**

Dyax Names Chief Medical Officer

Tess Schmalbach, M.D., Ph.D., has joined Dyax as senior VP of clinical and medical affairs and chief medical officer. Dyax, Cambridge, Mass., is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on cancer and inflammatory indications. Dr. Schmalbach has joined the company's senior-management team and is responsible for overseeing all clinical and medical affairs.

Previously, she was VP of clinical development for Coley Pharmaceutical Group. Board certified in clinical pharmacology, Dr. Schmalbach has a B.S. in biology and chemistry from Dickinson College; a M.D. from the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School; and a Ph.D. from the University of Rochester.

Biopharmaceutical **POOL**

George W. **COLE**

Encysive Appoints Chief Operating Officer

Encysive Pharmaceuticals, a biopharmaceutical company based in Houston, has appointed George W. Cole as chief operating officer.

In this newly created position, Mr. Cole oversees worldwide marketing, sales, and manufacturing operations in support of the anticipated launch of Thelin this year.

Mr. Cole previously spent more than 10 years with Altana Pharma U.S. in senior management roles, including president of the company's branded and generic businesses, as well as chairman of its global operating committee.

He has a MBA from the University of Evansville and a B.S. in pharmacy from the University of Louisiana.

Dr. N. Anthony **COLES**

NPS Names President, Chief Operating Officer

N. Anthony Coles, M.D., has been appointed to the newly created position of president and chief operating officer of NPS Pharmaceuticals, Salt Lake City.

NPS discovers, develops, and commercializes small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. Dr. Coles, 45, also has become a member of the NPS board of directors.

He most recently was senior VP of commercial operations at Vertex Pharmaceuticals. He earned his B.S. from Johns Hopkins University, his MPH from Harvard University, and his M.D. from Duke University.

Additionally, in mid-2006 Dr. Coles will succeed Hunter Jackson, Ph.D., as CEO. At that time, Dr. Jackson, who founded NPS in 1986, plans to step down and will remain a director of the company.

Dr. Mark D. **ERION**

Metabasis Therapeutics Appoints Chief Scientific Officer

Mark Erion, Ph.D., has been named chief scientific officer of Metabasis Therapeutics, a San Diego-based biopharmaceutical company focused on novel, small-molecule drugs to treat liver diseases.

Dr. Erion also continues to serve as the company's executive VP of research and development, a position he has held since 1997. Before joining Metabasis, he spent six years at Gensia, where he headed the research department.

He earned a B.S. in mathematics and chemistry from the University of Oregon and a Ph.D. in chemistry from Cornell University. He also was a National Institutes of Health postdoctoral fellow in enzymology at the Massachusetts Institute of Technology.

Thomas M. **ESTOK**

Conforma Therapeutics Hires Chief Commercial Officer

Conforma Therapeutics, a San Diego-based biopharmaceutical company, has appointed Thomas M. Estok to the newly created position of chief commercial officer.

Mr. Estok has almost 20 years of experience in the development and commercialization of pharmaceuticals. He comes to Conforma from Schering-Plough, where he most recently served as VP of U.S. marketing and commercial development within the oncology franchise.

He has a B.S. in biochemistry from Virginia Tech and a MBA from Fairleigh Dickinson University.

Dr. Philip **FROST**

ImClone Systems Appoints Interim CEO

ImClone Systems, New York, a biopharmaceutical company focused on oncology, has appointed Philip Frost, M.D., Ph.D., as interim CEO while the board conducts an external search for a permanent CEO.

Dr. Frost, who previously served as executive VP and chief scientific officer, has retained responsibility for the chief scientific officer function. He succeeds Daniel S. Lynch, who resigned after serving as the company's CEO since February 2004.

Before joining ImClone, Dr. Frost served as VP of oncology and codirector of the oncology therapeutic area leadership team at Wyeth. Before that, he served as a consultant for CaP Cure and as a VP of oncology for the Sandoz Research Institute.

Dee Parson **GRANGE** Dr. John Elliott **HUMPHRIES**

Glen **WILLIAMS**

Biolex Therapeutics Adds Key Managers

Biolex Therapeutics, a protein therapeutics company based in Pittsboro, N.C., has hired Dee Parson Grange as VP of business development. She is responsible for evaluating new Biolex protein opportunities, as well as ensuring current products in the pipeline achieve market value.



Ms. Grange joins Biolex from Bayer HealthCare, where she held various strategic and business operational positions for both pharmaceutical and biological products. She holds a B.S. in biology from Graceland

University and a MBA from Duke University.

John Elliott Humphries, M.D., has been appointed VP of development, responsible for leading the clinical development of Biolex's therapeutic protein candidates.

Dr. Humphries has more than 18 years of academic and pharmaceutical industry experience with a strong focus on hematology.

Before joining Biolex, Dr. Humphries served in a number of senior-level clinical development positions in the biologics division of Bayer HealthCare and most recently was director of global clinical strategy for several therapeutic proteins targeting congenital deficiency, hematology, cardiology, and vascular illnesses.

Dr. Humphries earned his A.B. in German and biology from Middlebury College and his M.D. from Johns Hopkins School of Medicine.

Glen Williams has been appointed senior VP of operations, responsible for Biolex's existing GMP operations and the design and implementation of the company's next-generation GMP production facilities.

Mr. Williams was previously the VP of manufacturing and general manager for Biogen Idec's Research Triangle Park, N.C., facilities. He holds a MBA from Central Michigan University and a B.S. in mechanical engineering from The Ohio State University.

Guillermo A. **HERRERA** NeoPharm Names President, CEO, and Director

NeoPharm, a biopharmaceutical company

based in Lake Forest, Ill., has appointed Guillermo A. Herrera as president, CEO, and director.

Mr. Herrera, 52, spent 24 years at Abbott Laboratories, most recently as senior VP of international operations and president of Abbott International. He has a B.A. in industrial economics from the Universidad del Valle, Colombia, and a MBA from the Kellogg Graduate School of Management at Northwestern University.

He succeeds Ronald G. Eidell, who served as interim president and CEO and who continues to serve as a director and a member of the company's audit committee.

Jeffrey H. **KNAPP**

Abgenix Appoints Senior VP, Sales and Marketing

Abgenix, Fremont, Calif., has appointed Jeffrey H. Knapp to the newly created position of senior VP of sales and marketing, responsible for building and leading the company's commercial capabilities. Abgenix is a biopharmaceutical company focused on the discovery, development, and manufacturing of fully human therapeutic antibodies.

Mr. Knapp has more than 15 years of commercial experience in therapeutic oncology. He served most recently as VP of sales and marketing at Pharmion. He has a B.A. in biology from Wittenberg University.

Richard W. **PASCOE**

Ariad Names Chief Commercial Officer

Ariad Pharmaceuticals has appointed Richard W. Pascoe to the newly created position of VP and chief commercial officer, responsible for developing and leading the marketing and sales organization. Based in Cambridge, Mass., Ariad discovers and develops breakthrough medicines that treat disease by regulating cell signaling with small molecules.

Since 2000, Mr. Pascoe has held a series of senior management roles at King Pharmaceuticals, where he most recently held senior VP positions in both marketing and sales. He has a B.S. in leadership studies from the U.S. Military Academy at West Point.

Dr. Gregory **SHOTZBERGER**

Icagen Expands Management Team

Icagen, a biopharmaceutical company based in Research Triangle Park, N.C., has

hired Gregory Shotzberger, Ph.D., as VP of business development.

Dr. Shotzberger has more than 20 years of business development experience in the pharmaceutical and biotechnology industries. Most recently, he was senior VP of business development for King Pharmaceuticals. He holds a Ph.D. in pharmacology from the State University of New York at Buffalo, a MBA in general management from the University of Delaware, and a B.S. in microbiology from The Pennsylvania State University.

Specialty **POOL**

Dr. Wesley W. **DAY**

Vivus Appoints VP, Clinical Development

Vivus, Mountain View, Calif., a specialty pharmaceutical company focused on restoring sexual function, has appointed Wesley W. Day, Ph.D., as VP of clinical development.

Dr. Day comes to Vivus after more than 12 years at Pfizer, where he most recently served as a senior director and therapeutic area head of oncology and ophthalmology.

He has a Ph.D. in pharmacology and toxicology from the University of Maryland at Baltimore and a B.S. from University of Texas Pan American.

Dr. Costantinos **EFTHYMIPOULOS**

Eurand Appoints Chief Scientific Officer



Eurand, Vandalia, Ohio, a specialty pharmaceutical company, has appointed Costantinos Efthymiopoulos, Ph.D., to the position of chief scientific officer, responsible for global research and development, clinical development, and regulatory affairs. Previously, he worked at Sero as corporate VP and head of the dermatology therapeutic area.

He has a bachelor of pharmacy degree from the University of Athens and a MBA from the London Business School. He also holds a M.Sc. in industrial pharmacy, a M.Sc. in molecular and cellular pharmacology and medicinal chemistry, and a Ph.D. in pharmacology (pharmacokinetics) from the University of Strasbourg.

Dr. Fred **FELDMAN**Bentley Pharmaceuticals
Names VP, R&D

Fred Feldman, Ph.D., has been appointed VP of research and development at Bentley Pharmaceuticals, Exeter, N.H., a specialty pharmaceutical company focused on advanced drug-delivery technologies and pharmaceutical products.

Dr. Feldman has more than 25 years of product development expertise. He previously served as senior VP, worldwide head of preclinical R&D, and head of biotechnology for Centeon and Aventis Behring, both Aventis Pharma subsidiaries. He has a B.S. in biochemistry from the University of Chicago and Ph.D. in biochemistry from Purdue University.

Dr. Everardus

ORLEMANSDr. Elly **SAVALUNY**

Pozen Adds VPs

Everardus Orlemans, Ph.D., has been named VP of clinical research at Pozen, Chapel Hill, N.C., a specialty pharmaceutical company focused primarily on products for the treatment of migraine, acute and chronic pain, and other pain-related conditions. He is responsible for all of the company's efforts in the conduct of clinical trials to support new drug application (NDA) submissions to the FDA and other worldwide regulatory bodies.

Most recently, Dr. Orlemans was executive director of the clinical development unit for Organon in the United States. He has a M.S. in chemistry from Catholic University of Nijmegen and a Ph.D. from the University of Twente.

Additionally, Elly Savaluny, Ph.D., has been named VP of biostatistics and data management at Pozen. Dr. Savaluny is responsible for the data management and statistical analysis of clinical trials to support NDA submissions to the FDA and other worldwide regulatory agencies.

He was global head of clinical operations, biostatistics, and data management at Novartis Consumer Health. He received a Ph.D. from the University of Reading, an M.Sc. in medical statistics from the London School of Hygiene and Tropical Medicine, and a graduate diploma in statistics from Portsmouth University.

Alan L. **RUBINO**Pharmaceutical Leader
Joins Pharmos

Pharmos has appointed Alan L. Rubino pres-

ident and chief operating officer. Located in Iselin, N.J., Pharmos discovers and develops novel therapeutics to neurological and inflammatory disorders.

Mr. Rubino replaces Gad Riesenfeld, Ph.D., who has been with Pharmos since 1992 and remains in a consulting role to ensure a smooth transition.

Most recently, Mr. Rubino was executive VP and general manager of PDI.

He holds a B.A. in economics from Rutgers University, where he also minored in biology and chemistry. He has attended executive programs at both Harvard Business School and the University of Lausanne.

Drug-Delivery **POOL**Jennifer L. **GOOD**Penwest Names President and
Chief Operating Officer

Penwest Pharmaceuticals, Danbury, Conn., has appointed Jennifer L. Good, as president and chief operating officer. Penwest develops pharmaceutical products based on innovative oral drug-delivery technologies.

Ms. Good, 40, originally joined the company as chief financial officer when it was founded in 1997. She was later promoted to senior VP, chief financial officer. She continues to be responsible for all aspects of Penwest's financial management.

Before this, she served as corporate controller and corporate director of finance for Penford, Penwest's former parent company. She has a bachelor's degree in business administration from Pacific Lutheran University.

Additionally, Robert J. Hennessey has relinquished his position as CEO and has returned to serving as a director of Penwest. Mr. Hennessey, 63, has been a director of the company since 1997. He has served as CEO since February 2005, when he was asked to come out of retirement to fill the position.

Device/Diagnostic **POOL**James M. **CORNELIUS**

Guidant Appoints Interim CEO

Guidant, Indianapolis, which designs and develops cardiovascular medical products, has

appointed James M. Cornelius as chairman and interim CEO.

Mr. Cornelius, who previously served as nonexecutive chairman, replaces President and CEO Ronald W. Dollens, who has retired after more than a decade at the company helm.

Before joining Guidant, Mr. Cornelius was at Eli Lilly since 1983, serving as a member of the board of directors of Lilly, on the executive committee, and as chief financial officer. He earned his B.A. in accounting, magna cum laude, and his MBA in finance from Michigan State University.

Joseph G. **DARLING**Sally L. **MAHER**Smith & Nephew Endoscopy
Appoints Executives

Smith & Nephew's Endoscopy division, based in Andover, Mass., has appointed Joseph G. Darling as VP of marketing. Smith & Nephew, London, is a global medical technology business specializing in endoscopy, orthopedics, and advanced wound-management products. Mr. Darling is responsible for Endoscopy's worldwide strategic marketing direction.

He has more than 20 years of experience in the medical industry, most recently as VP of marketing, U.S. medication delivery systems, at Baxter International. He is a graduate of Syracuse University.

Smith & Nephew Endoscopy also has appointed Sally L. Maher as VP of research and development.

Ms. Maher originally joined Smith & Nephew in 1999 and most recently served as the company's VP of government affairs. She has a bachelor's degree from the Ohio Wesleyan University and a law degree from the University of Baltimore.

Discovery **POOL**Dr. Steven R. **HAGEN**Pfizer Veteran Joins
Albany Molecular

Albany Molecular Research, Albany, N.Y., has hired Steven R. Hagen, Ph.D., as senior director of analytical quality services, responsible for overseeing all analytical chemistry efforts. The global, drug-discovery company provides chemistry services to pharmaceutical and biotechnology companies.

Dr. Hagen most recently was director of analytical research and development at Pfizer's Global Research and Development division.

He earned a Ph.D. in biochemistry and a master's degree in botany from the University of Idaho. He also has a B.A. in biology from Lawrence University.

Dr. Timothy **HENKEL**

PolyMedix Appoints Drug Development VP

Timothy Henkel, M.D., Ph.D., has been named VP of drug development and chief medical officer of PolyMedix, Philadelphia, a biomimetic drug design company.

He comes to PolyMedix from Vicuron Pharmaceuticals, where he was executive VP and chief medical officer. He earned his M.D. and Ph.D. degrees from the Washington University School of Medicine.

Dr. Virgil **LUCAS**

Alexander **SMITH**

Dr. Paul **STEED**

Senior Research and Development Executives Join Serenex



Serenex, an integrated, oncology-focused drug discovery and development company in Durham, N.C., has appointed Virgil (Sol) Lucas, Pharm.D., to the position of VP of clinical development. He is

responsible for all aspects of clinical development and serves as a member of the company's senior management team. Dr. Lucas joins Serenex from GlaxoSmithKline, where he was senior therapeutic area director of oncology, clinical pharmacology, discovery medicine.



Alexander (Lex) Smith has been appointed to the position of VP of technical development, responsible for all aspects of pharmaceutical development. He serves as a member of the senior management team. Mr.

Smith most recently was VP of drug product development for Fulcrum Pharma Developments.



Serenex has hired Paul Steed, Ph.D., as director of biology, responsible for the company's discovery biology programs. Dr. Steed previously served as executive director of pre-clinical biology at Amphora Discovery.

Association **POOL**

Dr. Edward **HELTON**

CDISC Names Chair-Elect



Edward Helton, Ph.D., has been named chair-elect for the Clinical Data Interchange Standards Consortium (CDISC), an independent, medical and biopharmaceutical standards organization based in Austin, Texas. A member of the CDISC board of directors since 2003, Dr. Helton becomes chairman in January 2007.

Dr. Helton is chief strategist of regulatory and biomedical affairs for SAS.

George **RATHBUN**

Chief Technology Officer of SAFE-BioPharma Named



George Rathbun has been named chief technology officer of SAFE-BioPharma Association, Whitehouse Station, N.J., a network that delivers electronic identity credentials for legally enforceable and regulatory compliant digital signatures. He also serves as chairman of the SAFE Technology and Implementation Working Groups and as the chief systems architect for SAFE. Mr. Rathbun is director of architecture in Pfizer's Global Research and Development Informatics organization.

Agency **POOL**

Shakira **ADAMS**

Patricia **COLELLO**

Christopher **LUZHAK**

Darah **SEMANKIK**

Karen **THOMPSON**

Altum Expands Staff

Altum, Parsippany, N.J., CommonHealth's full-service professional healthcare advertising agency has added new staff.



Shakira Adams has joined the agency as an account executive. She helps to manage the financial aspect of her accounts. Most recently, she worked as a legal assistant at Porzio, Bromberg & Newman.



Patricia Colello has been named VP, account group supervisor. She is responsible for all global activities involved in launching new oncology products. She was a VP, account supervisor, at Integrated Communica-

tions.

Christopher Luzhak has joined Altum as a copywriter. Mr. Luzhak previously was employed as a copywriter at ImageSmith.

Darah Semancik has joined the agency as an art director. Most recently, Ms. Semancik was a graphic designer at American Lawyer Media.

Karen Thompson has been named senior VP, management supervisor. She provides strategic analysis, positioning, and branding support to all agency clients. Ms. Thompson previously was employed at Ferguson as a senior VP, management supervisor.

Mary **BLACKSTOCK**

Julie **BRECHT**

Jamie **COBB**

Lainey **DIETZ**

Lynn **DINSMORE**

Kris **EARLY**

Kara **GOLUB**

John **JAKOVLIC**

Cory **MYERS**

Susan **ORZEL-BIGGS**

Lina **PEREZ**

Kristan **REID**

Christopher **SCHOBERT**

Dave **SONDERMAN**

GSW Worldwide Hires and Promotes

GSW Worldwide, Columbus, Ohio, a part

of the inChord Communications division of Ventiv Health Inc. and one of the largest healthcare advertising agencies in the world, has hired and promoted staff.

Mary Blackstock has joined the agency's New York office as design director, responsible for creative development on several of GSW's accounts. Previously, she served as designer at Pfizer. She holds a bachelor's degree from Sarah Lawrence College.

Julie Brecht has been named associate director of creative services. In this newly formed position, she helps lead the creative services department.



Jamie Cobb has been named senior VP/international creative director. He is responsible for leading the global creative wave, the creation of the global campaign book, and ensuring consistency in GSW Worldwide's creative liberating ideas.

Lainey Dietz has been named creative supervisor for one of GSW Worldwide's pharmaceutical accounts and is responsible for leading all creative service needs for the account.



Lynn Dinsmore has been named VP, director of creative services, responsible for leading and managing the creative services department.

Kris Early has been named VP/creative director. Ms. Early is responsible for leading the creative on four of GSW Worldwide's pharmaceutical accounts.



Kara Golub has been named account supervisor in GSW's public-relations practice, based in the New York office. She is the primary contact on all day-to-day account activity for the agency's public-relations accounts. Most recently, she was senior account executive at Marina Maher Communications. She has a bachelor's degree from the State University of New York at Albany.



John Jakovlic has been named VP, director of process excellence, responsible for leading the agency's Six Sigma program.

GSW has hired Cory Myers as senior art director, responsible for concept, design, presentation, execution, and production for one of the agency's pharmaceutical

accounts. He is based in New York. He previously served as senior art director at FCB Healthcare. Mr. Myers has a bachelor's degree from Kutztown University.

Susan Orzel-Biggs has been named director of editorial services, responsible for leading the editorial department and serving as account editor. She is based in New York. Most recently, she was director of editorial services at Saatchi & Saatchi Consumer Healthcare. Ms. Orzel-Biggs has a bachelor's degree from the City University of New York.

Lina Perez has joined GSW's New York office as account executive. She is the primary contact on all day-to-day account activity for two of the agency's consumer accounts. Previously, she served as account executive at Chinnici Direct. Ms. Perez holds a master's degree from New York University.

Kristan Reid has been named VP, management supervisor, responsible for managing several of the agency's pharmaceutical accounts. She is based in New York. Most recently, she was VP, account group supervisor, at Grey Healthcare. She holds a bachelor's degree from Pace University.

Christopher Schobert has joined GSW's New York office as director of creative operations, responsible for leading the agency's internal creative studio. Previously, Mr. Schobert served as director of studio services at Grey Healthcare. He has a bachelor's degree from the University of Wisconsin, Milwaukee.



Dave Sonderman has been named senior VP/group creative director. He oversees and manages the creative for several of GSW Worldwide's pharmaceutical accounts.

Jennifer **BURKHARDT**

Nicholas **CARRON**

Bryan **DUFFIE**

Aaron **REISER**

TJ **SOCHOR**

Blue Diesel Adds Staff

Blue Diesel, an interactive communications company based in Columbus, Ohio, has added new staff. Blue Diesel is part of the inChord Communications division of Ventiv Health Inc.

Jennifer Burkhardt has joined the agency as account manager. She previously served as performance-improvement consultant at Eli Lilly. Ms. Burkhardt holds a bachelor's degree from Indiana University.

Nicholas Carron has joined Blue Diesel as senior interactive designer. He most recently served as senior multimedia graphic designer at MindLeaders. He holds a bachelor's degree from Ohio University.

Bryan Duffie has been named interactive designer. Previously, he served as a graphic designer at The Voinovich Center for Leadership and Public Affairs at Ohio University. He has a bachelor's degree from Ohio University.

Blue Diesel has appointed Aaron Reiser as interactive art director. Most recently, Mr. Reiser was online creative manager and information architect for Real Living. He holds a master's degree from The School of the Art Institute of Chicago.

TJ Sochor joins the agency as media specialist. Previously, he served as motion graphics designer/creative director at SOS Video Communications. He holds a bachelor's degree from The Columbus College of Art and Design.

Bryan **CARSON**

S&R Communications Appoints Account Group Director



Bryan Carson has joined S&R Communications Group as account group director and team leader on the UCB Pharma and Prestwick Pharmaceuticals accounts.

He also is responsible for identifying new business opportunities for the Durham, N.C.-based healthcare marketing and communications company.

Most recently, Mr. Carson worked for Mylan Bertek Pharmaceuticals where he served as executive director of neurology marketing.

Michael **COSTELLO**

Palio Promotes



Palio Communications, a full-spectrum advertising and communications agency, and part of the inChord family of companies, has promoted Michael Costello to copywriter from editor.

He joins the Saratoga Springs, N.Y., agency from Vantage Press, where he served as a production editor and freelance editor.

Mr. Costello holds a master of fine arts degree from New School University and a bachelor's degree from the State University of New York at Fredonia.

Rita **DISTEFANO SCHUERMAN**

Jim **SHEA**

Vox Medica Adds Senior Staff

Vox Medica, an independent healthcare communications company based in Philadelphia, has promoted Rita DiStefano Schuerman to VP, group account supervisor, in the company's Healthcare Marketing Communications Group. In this role, Ms. DiStefano Schuerman directs strategic planning and programs while working to expand business.

She has more than 10 years of experience in account supervision and project management. She received her bachelor's degree in mechanical engineering from Drexel University, and she participated in the HMCC Management Development Program through the Tuck School of Business at Dartmouth University.



Additionally, Vox Medica has hired Jim Shea as a copyeditor/proofreader. Mr. Shea has more than 30 years experience in editing, proofreading, and writing in the medical communications, pharmaceutical,

and publishing industries. He holds a bachelor's degree in physics from Northeastern University and is a member of the American Medical Writers Association.

Jennifer **FAJNOR**

Barbara **KELLY**

Michele **MOSS**

Pat **ROQUE**

Dawn **SCHOLZ**

Carbon Expands Staff



Jennifer Fajnor has joined Carbon, Wayne, N.J., CommonHealth's professional advertising and promotion agency created to serve the marketing needs of emerging technology/specialty brands. As a group art supervisor, she is responsible for overseeing the art direction for one of the agency's fastest-growing specialty clients. She previously was an art supervisor at Torre Lazur McCann.

Carbon has hired Barbara Kelly as a VP, account group supervisor. Most recently, Ms.



Kelly was at Torre Lazur McCann as a VP, account group supervisor.



Michele Moss has been named a senior VP, creative director/copy. In this position, she spearheads the creative copy direction and copywriting for one of the agency's fastest-growing specialty clients. She also guides and mentors copywriters within her group. Most recently, Ms. Moss was a VP, associate creative director, at Torre Lazur McCann.



Pat Roque has joined Carbon as an account supervisor. Previously, Ms. Roque served as a director at Emron.

Dawn Scholz has been named as a business manager. Most recently, Ms. Scholz was a production manager at Medco.

David **SCHULL**

Noonan Russo Names Managing Director of California Office



Noonan Russo, the corporate communications division of Euro RSCG Life PR, New York, has appointed David Schull as senior VP and managing director of the agency's California office, located in San Diego.

A public relations and marketing communications professional with more than 13 years of agency leadership experience, Mr. Schull focuses on expanding Euro RSCG Life PR and Noonan Russo's operations in California and on the West Coast.

Most recently, he was the senior VP of Thorp & Co.

He has a J.D. from the University of Miami School of Law and a bachelor's degree in journalism from the University of Colorado School of Journalism and Mass Communications.

Roger **VIOLA**

DVC HealthCare Appoints Senior VP

Roger Viola has been named senior VP of strategic client partnerships at DVC HealthCare, a medical marketing agency based in Yardley, Pa.

Mr. Viola has 24 years of experience in the



healthcare industry, most recently as VP and general manager of the U.S. office of Complete Medical Communications, a division of McCann Healthcare Worldwide. He is a graduate of the University of Pennsylvania and earned the CMR designation from the Certified Medical Representatives Institute.

Sarah **WILCOX**

Draft Promotes Executive VP



Sarah Wilcox has been promoted to executive VP and director of Draft Health. Draft Health is a division of Draft, Chicago, a global, behavior-based, communications company.

Ms. Wilcox joined Draft Chicago less than

two years ago as senior VP in charge of the firm's healthcare division.

She has more than 20 years experience as a marketing executive and management consultant for biotechnology companies, hospitals, public health programs, medical products, healthcare organizations, nutraceutical, and cosmeceutical marketers.

Ms. Wilcox is a graduate of the University of Buffalo, and she has a MBA from the Kellogg Graduate School of Management at Northwestern University.

Consulting **POOL**

Mark **BUNGER**

Lux Research Hires Senior Analyst

Lux Research, New York, a research and advisory firm focusing on the business and economic impact of nanotechnology, has further expanded the firm's West Coast operations by hiring Mark Bunger as a senior analyst.

He is based in the company's San Francisco office. Mr. Bunger brings to Lux 14 years of business strategy experience, both as a management consultant and technology analyst. Most recently, he was a principal analyst at Forrester Research.

Mr. Bunger has studied international marketing at Mälardalen Polytechnic in Sweden; market research at the University of Texas; and biochemistry at the University of California at Berkeley's extension program.

Anne **CHAPMAN**

TVG Appoints VP



TVG Marketing Research & Consulting, Dresher, Pa., has appointed Anne Chapman, to the position of VP of strategic account management. TVG is a leading pharma marketing research firm. Ms. Chapman is responsible

for building new client partnerships by leveraging her insights into the current needs and the current business issues facing pharmaceutical marketers and marketing researchers.

She has more than 25 years of experience in senior sales management, sales consulting, business development, and relationship management. She previously held positions as associate VP of business development for G&S Research and director/senior consultant for P/S/L Research.

Dr. Richard **KULKA**

Abt Appoints Senior VP, Strategic Business Development

Richard Kulka, Ph.D., has been named senior VP of strategic business development at Abt Associates, a government and business research and consulting firm in Cambridge, Mass. Dr. Kulka, who also has joined the company's management team, plays a major role in helping accelerate growth in key markets.

He brings to Abt more than 30 years of experience in social science research and management. He spent the last 11 years with RTI International, most recently as executive VP of the social and statistical sciences group. He has a Ph.D. in social psychology from the University of Michigan, an M.A. in sociology from the University of Michigan, and a B.A. in sociology from Tulane University.

CRO **POOL**

Mary **BRIGGS**

Elizabeth **JENKINS**

Kendle Adds Senior Staff

Kendle, a global, full-service CRO based in Cincinnati, has appointed Mary Briggs as senior director of new business development. She is responsible for building strategic business relationships with Kendle's biopharma-



ceutical customers and for continuing to expand the company's Phase I to Phase IV clinical development business worldwide.

Ms. Briggs brings nearly two decades of experience to Kendle's new business development

team. She most recently served as VP of strategic account management, responsible for new business efforts in the areas of neurology, psychiatry, analgesia/pain, critical care, and infectious disease.



Additionally, Kendle has appointed Elizabeth "Liz" Jenkins as principal regulatory consultant in its Ely, United Kingdom, office. She is responsible for providing senior-level strategic regulatory input for Kendle's biotechnolo-

gy projects.

She brings to Kendle more than 20 years of regulatory experience. She most recently spent seven years as an independent consultant and previously was the associate director of regulatory affairs for a major pharmaceutical company's European operations.

Medical-Education **POOL**

Tom **DRAKE**

Dr. Emmanuelle

HUGENTOBLER

Caudex Medical Expands U.S. Office

Tom Drake has been named general manager of the U.S. office of Caudex Medical and Scientific Frontiers, Oxford, England, a global medical education and communications company. Caudex Medical acquired Scientific Frontiers in 2005. Both companies are part of McCann Healthcare Worldwide. Mr. Drake leads the U.S. operations, based in Newtown, Pa., providing strategic medical communication services for both domestic and global clients. He previously worked for Dorland Global Health Communications.

Additionally, Emmanuelle Hugentobler, M.D., Ph.D., has been named senior VP, medical director of Caudex Medical's U.S. office. Dr. Hugentobler provides medical and strategic guidance to clients' programs and initiatives and leads the internal scientific staff. Pre-

viously, he was management supervisor at Torre Lazur McCann.

Dr. Terry Ann **GLAUSER**

Scinexa Names Medical Director



Scinexa, a medical-education company based in Plainsboro, N.J., has named Terry Ann Glauser, M.D., as medical director. She oversees content development for each of Scinexa's continuing education activities,

ensuring that the content fills a need in education while maintaining the proper standards in fair balance.

Before joining Scinexa, Dr. Glauser consulted for Medical Broadcasting Company, Cadient Group, Axis Healthcare Communications, Physicians' Practice, NetPlus Marketing, and Johnson & Johnson Healthcare Systems.

Dr. Glauser has a B.A. in chemistry from Bryn Mawr College, a M.D. from Jefferson Medical College, and a MPH from the Johns Hopkins School of Hygiene and Public Health. She completed her residency at the Thomas Jefferson University Hospital.

Edward J. **HEINZ**

HealthSTAR Educational Systems Names VP, Account Services

Edward J. Heinz has been named VP of account services for HealthSTAR Educational Systems, a division of HealthSTAR Communications, a healthcare marketing services network based in Woodbridge, N.J. In this role, he supports account management initiatives and works on the development of branded educational solutions.

Mr. Heinz recently held positions at SynerMed Communications and Health Learning Systems. He has a B.A. in biology from Tusculum College and a certificate in pharmaceutical marketing from the Pharmaceutical Advertising Council.

Rhonda **HUNT**

Curry Rockefeller Adds Program Director



The Curry Rockefeller Group, a medical-education company based in Tarrytown, N.Y., has appointed Rhonda Hunt as program director.

A registered nurse, Ms. Hunt has experience in nursing and medical



Advance Pharmaceutical Medicine and your Clinical Research Center



April 28-30, 2006
Phoenix, AZ
www.acrp2006.org

The 3-day Academy of Pharmaceutical Physicians and Investigators (APPI) Program at the ACRP Global Conference & Exhibition is a unique educational opportunity for pharmaceutical physicians and physician investigators.

With the program theme, **"In a Common Voice: Pharmaceutical Physicians, Physician Investigators and the Future of APPI,"** physicians on "both sides" of drug and medical device development (study

sponsors and clinical trials sites) will converge in Phoenix, April 28-30, to network and exchange ideas, share information on the scientific, regulatory, ethical and business aspects of clinical research, and earn continuing medical education (CME) credits. The event will include discussions on conflicts of interest, ethical misconduct, pharmaceutical medicine as a medical specialty, and the public perception of clinical research.

For more information and to register, visit www.acrp2006.org or call APPI at 1-866-225-2779 for a free information kit on the Academy of Pharmaceutical Physicians and Investigators Program. See you in Phoenix!



education. She most recently served as associate account manager with The Scienomics Group. She holds a degree in nursing from the Watts School of Nursing.

Service POOL

Denise **DIXON**

WRB Communications Promotes VP, Marketing and Sales

Denise Dixon has been promoted to VP of marketing and sales at WRB Communications, Chantilly, Va., a contact center serving the pharmaceutical, biotechnology, and medical-device industries. She has primary responsibility for leading strategic marketing initiatives and client development across all markets.

Ms. Dixon is an active member of the Drug Information Association and Healthcare Businesswomen's Association.

Anthony **KELLY**

Clinical Financial Services Hires Executive VP

Clinical Financial Services, Audubon, Pa., has hired Anthony Kelly as executive VP. Clinical Financial is a privately held financing and financial services management company focused exclusively on the clinical trials industry. In this newly created position, Mr. Kelly is spearheading the firm's sales and marketing efforts.

He previously held management positions in the pharmaceutical and medical device industries with Merck, Mentor, and PhotoMedex. He has a degree in accounting from LaSalle University.

Richard **KOLLENDER**

Dr. Matt **RIEKE**

Dr. Geeta **VEMURI**

Quaker BioVentures Promotes Key Members of Investment Team



Quaker BioVentures, Philadelphia, a venture capital firm dedicated to investing in life-sciences companies in the Mid-Atlantic region, has promoted Richard Kollender to partner.

Mr. Kollender joined Quaker BioVentures as a principal in early 2003.

Previously, he worked at GlaxoSmithKline, where he held positions in sales, marketing, worldwide business development, and venture capital. He holds a B.A. from Franklin and Marshall College and MBA and health administration and policy degrees with honors from the University of Chicago.



Matt Rieke, M.D., also has been promoted to partner. Dr. Rieke was a founding principal of Quaker BioVentures. Previously, he was a principal at PA Early Stage where he invested in early-stage life-sciences companies.

He has a B.A. from Colgate University, an M.D. from the University of Pennsylvania, and a MBA from the Wharton School.



Geeta Vemuri, Ph.D., has been named VP of Quaker BioVentures. She originally joined the firm in 2003 as a senior associate. Previously, she was an associate at Toucan Capital. Dr. Vemuri earned her Ph.D. in biochemistry

from the Indian Institute of Sciences and a MBA from the Wharton School.

Whitney **STUART**

FFF Enterprises Builds National Accounts Team

FFF Enterprises, Temecula, Calif., a healthcare corporation that manages and distributes biopharmaceuticals and vaccines, has appointed Whitney Stuart as VP of national accounts. In this newly created position, she works closely with FFF's group purchasing organization customers and manufacturer partners.

Ms. Stuart most recently worked for the American Red Cross, as the national director of corporate accounts. She has a MBA from George Washington University and a B.S. in biology from the University of Tennessee.

Glenn C. **VAN DEUSEN**

Parexel Names General Manager of Medical Marketing Services



Parexel International, Waltham, Mass., a global biopharmaceutical services organization, has appointed Glenn C. Van Deusen as corporate VP and general manager of medical marketing services. He has global leadership for all

medical marketing business units, including medical education and communications, exhi-

bitions, meetings and events, reimbursement and patient-assistance programs, health policy, and scientific publications.

He most recently served as executive VP and managing director of the Saatchi & Saatchi Healthcare Division of Publicis Groupe. He also has extensive client-side experience through at Advanced Polymer Systems, Bausch & Lomb, Procter & Gamble, and SmithKline Beecham.

Mr. Van Deusen is primarily based in Stamford, Conn., but he also manages global efforts from the company's offices in England.

Technology-Web POOL

Dr. Graham **BUNN**

Executive Joins Medidata



Graham Bunn, Ph.D., has been named VP of strategic alliances for EMEA at Medidata Solutions Worldwide, New York, a global provider of electronic clinical data capture, management, and reporting solutions.

Dr. Bunn brings more than 15 years of experience delivering strategic electronic data capture and management solutions to pharmaceutical companies worldwide. Most recently, he was global VP of e-clinical business development at Quintiles, where he worked for more than 10 years.

Suzanne **SULLIVAN**

MTI Information Technologies Names VP



MTI Information Technologies has appointed Suzanne Sullivan to the newly created position of VP of business development. Based in Langhorne, Pa., MTI offers proprietary, demand-generating products for pharmaceutical marketers using sophisticated, data-driven technologies.

She has more than 10 years of related industry experience, most recently as director of sales at NDCHealth. She holds a B.A. in economics from the University of Richmond.

Please send your personnel announcements to feedback@pharmavoice.com.